1%环吡酮胺香波治疗头皮脂溢性皮炎的双盲对照试验

成人型脂溢性皮炎是一种多见的皮肤炎症性疾病 ,其发病与糠秕马拉色菌有关。该研究验证了 1%环吡酮胺 (ｃｉｃｌｏｐｉｒｏｘｏｌａｍｉｎｅ)香波治疗头皮脂溢性皮炎的疗效和安全性。试验预先设计采用随机、双盲、安慰剂对照。对象为 15岁以上的轻度到中度头皮脂溢性皮炎 ,参照临床症状 :红斑、脱屑、瘙痒分别和综合评分。该次试验共有 10 2例患者入选 ,53例在治疗组(使用 1%环吡酮胺香波 ) ,4 9例在对照组 (使用婴儿香波 ) ,有 2 0例患者 (每组 10例 )未完成试验疗程。患者用香波洗发 ,每次 5分钟 ,每周两次 ,连用 4周 ,停止治疗后再随访两…     

丹参酮联合酮康唑治疗头皮脂溢性皮炎疗效观察

目的:评价丹参酮联合酮康唑治疗头皮脂溢性皮炎的疗效。方法:86例头皮脂溢性皮炎患者,随机分成2组。治疗组47例口服丹参酮加外用酮康唑,对照组39例口服复合维生素B加外用酮康唑,4周末观察疗效。结果:治疗组和对照组痊愈率分别为74.5%、53.8%(P0.05),有效率分别为100%、82.1%(P0.05)。结论:丹参酮联合酮康唑治疗头皮脂溢性皮炎疗效好,安全性高。     

吡硫翁锌气雾剂治疗头皮脂溢性皮炎疗效观察

目的 探讨吡硫翁锌气雾剂治疗头皮脂溢性皮炎的临床疗效和安全性.方法 将58例患者随机分成两组,试验组(30例)外用吡硫翁锌气雾剂,对照组(28例)外用2%酮康唑洗剂.疗程8周,每4周复诊1次,观察疗效及不良反应.结果 治疗4周后,试验组和对照组有效率分别为76.67%和46.43%;治疗8周后,两组有效率分别为90.00%和60.71%.两组均未见明显不良反应.结论 吡硫翁锌气雾剂治疗头皮脂溢性皮炎安全有效.     

2%采乐洗剂治疗头皮脂溢性皮炎和头皮糠疹（头皮屑）疗效观察

２％采乐洗剂治疗头皮脂溢性皮炎和头皮糠疹（头皮屑）疗效观察杨铭森①谢江淮①应秀玲①彭秀银①刘培生①１９９６年２月～６月，我科采用西安杨森公司生产的２％采乐洗剂（２％酮康唑洗剂），治疗３０例头皮脂溢性皮炎和头皮糠疹患者，取得较好的疗效，现简要小结如下。...     

采乐洗剂治疗头皮脂溢性皮炎36例

采乐洗剂治疗头皮脂溢性皮炎３６例李田顺（浙江建德市三院皮科３１１６１２）我科采用采乐洗剂（２％酮康唑洗剂）治疗头皮脂溢性皮炎并与希尔生作对比治疗，取得满意疗效。现报告如下：一、临床资料治疗组３６例，均为门诊诊断明确的头皮脂溢性皮炎患者。其中男２１例；...     

2%采乐洗剂治疗脂溢性皮炎和头皮糠疹（头皮屑）250例临床观察

２％采乐洗剂治疗脂溢性皮炎和头皮糠疹（头皮屑）２５０例临床观察张宁①脂溢性皮炎是皮肤科的常见病和多发病。临床上表现为头皮屑增多、瘙痒，重者多油、小丘疹和痂壳，常伴有不同程度的脱发。本文用２％采乐洗剂治疗头皮脂溢性皮炎和头皮糠疹（头皮屑）２５０例，现报...     

头皮屑和头皮脂溢性皮炎患者头皮脂类水平及马拉色菌数量的检测

目的:测定有头皮屑及头皮脂溢性皮炎患者与正常受试者头皮表面脂类水平及马拉色菌数量的差异。方法:使用sebumeter于洗发后连续4天测量受试者额、顶、枕部头皮皮脂,并于第4天真菌镜检马拉色菌,记录马拉色菌数量。结果:有头皮屑及头皮脂溢性皮炎组与正常对照组相比,马拉色菌数量显著增高,具有统计学意义(P<0.05)。头皮脂溢性皮炎组较头皮屑组的马拉色菌数量显著增高,具有统计学意义(P<0.05)。在头皮屑及头皮脂溢性皮炎组中,随着炎症程度加重,检出的马拉色菌孢子数增多。结论:马拉色菌感染可能与头皮屑多和脂溢性皮炎有关。     

凉血五花汤治疗面部激素依赖性皮炎有效性和安全性的Meta分析

目的 系统评价凉血五花汤治疗面部激素依赖性皮炎（FHDD）的有效性和安全性。方法 计算机检索美国国立医学图书馆全文数据库（PubMed）、生物医学文献数据库（Embase）、The Cochrane图书馆、中国生物医学文献数据库（CBM）、中国知网（CNKI）、万方数据库和维普中文期刊数据库,检索时限为自数据库建立至2021年4月30日,筛选凉血五花汤治疗FHDD的随机对照试验（RCT）。由2名研究者独立筛选文献、提取资料及评价纳入研究的偏倚风险后,采用RevMan5.4软件进行数据分析。结果 共纳入6项RCT,共计511例FHDD患者。Meta分析结果显示,与常规药物治疗对照组比较,联合凉血五花汤治疗研究组FHDD能够提高临床愈显率[相对危险度（RR）=1.53,95%可信区间（95%CI）为（1.17,2.00）,P=0.002],改善皮肤红斑[均数差（MD）=51.47,95%CI(21.48,81.45),P=0.0008],降低经皮水分丢失[MD=6.76,95%CI(6.34,7.17),P<0.000 01];但未增加不良反应发生率的风险[RR=1.08,95%CI...     

煤焦油洗剂（泽它洗剂）治疗头皮脂溢性皮炎疗效观察

煤焦油洗剂（泽它洗剂）治疗头皮脂溢性皮炎疗效观察杨莉佳①头皮脂溢性皮炎是临床上常见的皮肤病，治疗的方法比较多，但疗效不十分满意，我们使用１％的煤焦油洗剂外用治疗，取得了较好的临床效果，现总结报告如下。１临床资料所有患者均来自皮肤科门诊，共２２例，其中...     

泽它洗剂治疗头皮银屑病及脂溢性皮炎的临床疗效观察

泽它洗剂治疗头皮银屑病及脂溢性皮炎的临床疗效观察吴建华①黄平②廖万清①银屑病及脂溢性皮炎是常见并易复发的慢性炎症性皮肤病，外用药物能够控制症状，但是头皮银屑病和头皮脂溢性皮炎，由于发病部位特殊，给患者外用药物带来不方便。最近我们用山东德美克制药有限公...     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Pathogenic role of IL-17 in psoriasis and psoriatic arthritis

Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics.Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.